Skip to content

Evaluating the effects of exercises in patients with thalassemia major

Evaluating the effects of cardiac rehabilitation exercises (aerobic and endurance exercises) on cardiac function, functional capacity, quality of life and mental health of patients with thalassemia major

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230515058202N1
Enrollment
50
Registered
2024-01-24
Start date
2023-10-23
Completion date
Unknown
Last updated
2024-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thalassemia major disease. Beta thalassaemia

Interventions

Intervention 1: Intervention group: People in the intervention group do 8 weeks of planned rehabilitation exercises.The exercise program includes aerobic and resistance exercises. The aerobic exercise

Sponsors

Bandare-abbas University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Thalassemia major patients who undergo regular blood transfusions and receive packed cells every month. Patients receiving iron chelator with regular blood transfusion such as desferal or deferiprone at the same time. Left ventricular ejection fraction equal to or more than 50% New York Heart Association (NYHA) functional class I, II, or III. Being in the age range of 18 to 40 years Having the desire and motivation to participate in the training program

Exclusion criteria

Exclusion criteria: Severe exercise intolerance uncontrolled arrhythmia, uncontrolled angina pectoris, severe kidney or lung disease, musculoskeletal or neuromuscular conditions that preclude exercise or exercise testing, and signs or symptoms of ischemia and abnormal hemodynamic responses during previous incremental exercise test, suffering from severe mental and psychiatric diseases, use of psychoactive drugs, uncontrolled blood pressure and diabetes, clinical evidence of other secondary causes of pulmonary hypertension including HIV infection, hepatitis virus infection, Collagen vascular diseases, cirrhosis, chronic obstructive airway diseases and acquired heart disease associated with pulmonary hypertension.

Design outcomes

Primary

MeasureTime frame
Ferritin. Timepoint: Before the intervention and after the intervention. Method of measurement: Serum ferritin level by chemiluminescence method with Abbott Architect i1000SR Immunoassay System.

Secondary

MeasureTime frame
Quality of Life. Timepoint: Before the intervention and after the intervention. Method of measurement: SF-36 questionnaire.;Mental health. Timepoint: Before the intervention and after the intervention. Method of measurement: SCL-90-R questionnaire.;HR Recovery. Timepoint: Before the intervention and after the intervention. Method of measurement: exercise test.;Exercise capacity. Timepoint: Before the intervention and after the intervention. Method of measurement: 6-minute walk test.;Cardiac function. Timepoint: Before the intervention and after the intervention. Method of measurement: Echocardiography.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactzahra saadat

Bandare-abbas University of Medical Sciences

saadatzahra@gmail.com076-33333280-9

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026